Category: Uncategorized

SHENZHEN, China, Sept. 3, 2024 /Xinhua-AsiaNet/–

In September 2021, the Plan for Comprehensively Deepening Reform and Opening-up of the Qianhai Shenzhen-Hong Kong Modern Service Industry Cooperation Zone (Qianhai Plan) was released to outline the future development of Qianhai. Over the past three years, Qianhai, a hub for high-level opening-up, has been forging ahead with reform and innovation and delivering tangible results, noted by the Authority of Qianhai Shenzhen-Hong Kong Modern Service Industry Cooperation Zone recently.

Through reform and opening-up, Qianhai aims to become a new engine for the construction of the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) and the Shenzhen Pilot Demonstration Zone. Institutional innovation is one of Qianhai’s distinctive features. To date, Qianhai has gradually established the “Qianhai Model” for institutional innovation in key areas such as investment facilitation, trade facilitation, financial openness and innovation, and legal innovation.

A string of innovative measures have been launched, such as the administrative confirmation system for business registration, one integrated license, a suspension registration system for businesses, and the Qianhai e-Services Hong Kong-Macao Station. Latest statistics show that Qianhai has launched 241 new institutional innovation achievements since 2021, bringing the total to 835, with 36 of these being promoted nationwide, making a cumulative total of 94. According to the institutional innovation index of China’s free trade pilot zones released by Sun Yat-sen University, Qianhai has ranked first for three consecutive years.

Innovations in the financial field are viewed as one of the institutional innovations with the most typical Qianhai characteristics. In recent years, a series of financial innovation policies have been implemented here, covering aspects such as finance for people’s livelihood, the interconnectivity of the financial market, the development of modern finance industries, the facilitation of cross-border trade and investment, and enhanced cooperation in financial regulation.

“The deep atmosphere of financial businesses in Qianhai enables us to seek cooperation opportunities and achieve win-win success,” said Pan Rui, President of WeLab Group in China. “With the successful implementation of numerous financial innovation cases, Qianhai has become a preferred destination for Hong Kong residents and enterprises going north. A growing number of Hong Kong residents and enterprises have gathered in Shenzhen for development. More financial talents from Hong Kong have chosen to stay in Qianhai, contributing to its future development,” she added.

“The new Hong Kong Enterprise Loan policy provides a new cross-border financing channel for small and micro enterprises (SMEs) like us to seek development in Qianhai. In the past, the operational and credit records of the headquarters in Hong Kong could not be used to support our Qianhai branch in applying for bank loans. With the implementation of the Hong Kong Enterprise Loan policy and the Shenzhen-Hong Kong cross-border credit investigation cooperation, it has opened up new channels for bank loans,” said You Zunni, the head of Gangshun (Shenzhen) International Trade Co., Ltd.

LAiPIC is also one of the beneficiaries of the institutional innovations in Qianhai. In response to the Homecoming Action Plan launched by Qianhai, the company moved its office back to Qianhai in 2019. However, LAiPIC encountered some difficulties on the way back home. At that time, digital and creative companies like LAiPIC could not be listed under the cultural industry or the technological industry. As a result, the company was not entitled to any form of policy support. To address this problem, relevant authorities in Qianhai conducted on-site research at the company and innovatively formulated a wide range of policies for digital and creative industries.

“As the industry evolves rapidly, LAiPIC may not be where it is today without the valuable support or the timely release of support policies,” said Quan Xinghui, co-founder of LAiPIC. When the company encountered a bottleneck during its rapid development, the rapid and efficient implementation of these policies enabled it to set a benchmark, significantly advancing the industry’s growth.

Qianhai’s institutional innovation achievements in key areas such as law, finance, and government affairs have demonstrated its advantages in institutional innovation. This innovation not only helps Qianhai accelerate its comprehensive deepening of reforms but also provides new momentum for Qianhai to advance the comprehensive deepening of reforms in the Greater Bay Area and even China. “Qianhai has unparalleled policy advantages, and we also hope enterprises in Qianhai will continue to benefit from it and embrace greater opportunities,” said Pan Rui during the interview.

Source: The Authority of Qianhai Shenzhen-Hong Kong Modern Service Industry Cooperation Zone

–BERNAMA

· Dr. Scholl is a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest ever natural history study of Stargardt disease

SAN DIEGO, Sept 2 (Bernama-GLOBE NEWSWIRE) — Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its board of directors has appointed Hendrik P. N. Scholl, MD, MA, as the Chief Medical Officer of the Company, effective immediately. Dr. Scholl is the foremost globally recognized authority on Stargardt disease and age-related macular degeneration (AMD), bringing decades of expertise in treating retinal diseases, including the two key indications targeted by Belite Bio’s lead drug candidate, Tinlarebant.

“Dr. Scholl has pioneered some of the most significant ophthalmology advancements of our time, and we are incredibly honored and excited to welcome him as our Chief Medical Officer,” said Dr. Tom Lin, Chairman and CEO of Belite Bio. “Dr. Scholl has served as Chair of the Data and Safety Monitoring Board for both our Phase 2 and Phase 3 Stargardt disease trials, and his decision to join Belite further validates our belief in Tinlarebant’s immense potential to improve the lives of patients living with debilitating macular diseases. His leadership, expertise, and commitment to addressing this area of high unmet need has and will continue to be invaluable as we advance our clinical programs.”

“I am excited to join Belite Bio at this pivotal time in the Company’s development,” said Dr. Scholl. “I have dedicated my career to improving the lives of people suffering from serious retinal and macular diseases, and I am deeply impressed by Belite Bio’s pioneering approach to developing transformative therapies for Stargardt disease and dry AMD, which have historically lacked effective treatment options. I look forward to working with the team to advance these programs and bring hope to patients around the world.”

Dr. Scholl served as the founding and scientific co-director of the Institute of Molecular and Clinical Ophthalmology Basel (IOB) and Professor of Ophthalmology at the University of Basel, where he also led the Department of Ophthalmology as its Chairman. He currently serves as President of the European Vision Institute as well as Chairman of the largest clinical research network in ophthalmology in Europe, EVICR.net, and its Expert Committee on Retinal Dystrophies. He is also the Founder and President of the Swiss Association for Research in Vision and Ophthalmology (ARVO-SWISS).   

Dr. Scholl’s distinguished career in academia includes leadership positions at several key academic institutions. Recently, he served as Professor of Ophthalmology and Endowed Chair at the Wilmer Eye Institute of Johns Hopkins University Medical School. At the Johns Hopkins Hospital, he was the Head of the Retinal Degeneration Clinic and the Director of the Visual Neurophysiology Service. For the Wilmer Eye Institute, he also served as the Co-director of the Johns Hopkins Center for Stem Cells and Ophthalmic Regenerative Medicine.

Dr. Scholl is the coordinating principal investigator of the largest natural history study of Stargardt disease (ProgStar Study), which enrolled 365 subjects. Throughout his career, he has participated in over 10 clinical studies both in Stargardt disease and AMD, authored over 280 articles and reviews in peer-reviewed journals, and received numerous prestigious awards, including the European Vision Award, the President’s Award of the American Society of Retinal Specialists, the W. Richard Green Award and the Paul Henkind Memorial Award of the Macula Society, the Swiss Alfred-Vogt Award, and the Kupfer award of ARVO. He holds an honorary doctorate from Semmelweis University in Budapest, Hungary, and is Adjunct Professor at the Medical University of Vienna, Austria.

Over the course of his 25 years of experience, Dr. Scholl has led and participated in numerous boards and advisory committees. He currently serves on the Scientific Advisory Board of Pro Retina Deutschland, Foundation Fighting Blindness, Erasmus University Medical Center, AIBILI, and the Institut de la Vision (Paris); on the Investment Advisory Board of Droia NV; and the Data Safety Monitoring Board of Roche Holding AG and ViGeneron GmbH.

Dr. Scholl graduated from the University of Tübingen, Germany with a Doctor of Medicine (Dr. med.) and Master of Arts. He completed his specialist training at the University Eye Hospital in Tübingen before being awarded a fellowship from the German Research Foundation (DFG) at Moorfields Eye Hospital and Institute of Ophthalmology in London, and a DFG Heisenberg Professorship for Macular Diseases at the Eye Clinic of the University of Bonn, Germany.

About Belite Bio

Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have significant unmet medical needs such as Stargardt Disease and Geographic Atrophy in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent Stargardt subjects and a Phase 3 study (PHOENIX) in subjects with Geographic Atrophy. For more information, follow us on Twitter, Instagram, LinkedIn, Facebook or visit us at www.belitebio.com.

Media and Investor Relations Contact:
Jennifer Wu : ir@belitebio.com
Julie Fallon : belite@argotpartners.com

SOURCE: Belite Bio, Inc

–BERNAMA

KUALA LUMPUR, Aug 27 (Bernama) — Varian, a Siemens Healthineers company, announced the launch of HyperSight imaging solution for its TrueBeam and Edge systems across the Asia Pacific (APAC) region (excluding China).

This upgrade gives clinicians unparalleled image quality, enhancing their ability to deliver precise and efficient radiation therapy treatments, as HyperSight optimises workflows across Varian’s entire suite of linear accelerators, enabling more tailored treatment for each patient.

“Guided by the evolving needs of radiation therapy based on current clinical trends, this innovation exemplifies our commitment to advancing clinical practice and providing high quality solutions for cancer patients everywhere.

“By combining advanced imaging with precise treatment delivery, we empower clinicians to deliver superior care,” said Varian APJ President, Hideaki Mori in a statement.

HyperSight acquires high-quality images and offers an extended field of view during a patient’s daily radiation treatments, which is particularly beneficial for treating large cancers.

This facilitates accurate tumour volume targeting, reduces target volume margins, and preserves healthy tissue. It provides Hounsfield Unit (HU) accuracy needed for treatment planning directly on the acquired conebeam CT (CBCT) images, allowing clinicians to calculate changes in tumours and surrounding organs with greater precision, helping to adjust treatments more effectively.

This eliminates the need for separate CT scans, potentially avoiding extensions to a patient’s hospital stay. HyperSight is designed for all anatomical sites and has a 50 per cent faster gantry rotation compared to traditional CBCT scans, which can take up to 60 seconds.

For existing TrueBeam and Edge users, the upgrade seamlessly integrates with their systems, reducing motion-related artefacts due to patient movement and minimising discomfort from prolonged treatment times.

Varian is committed to supporting healthcare providers with an innovative portfolio of radiotherapy solutions, including HyperSight, and is working with regulators to review reimbursement models to support optimal patient care.

— BERNAMA

AsiaNet 0200337

TOKYO, Aug. 26, 2024 /Kyodo JBN/ —

Cosmos Hotel Management Co., Ltd., which operates Japan’s No. 1 apartment hotel “MIMARU,” will exhibit at the travel fair “MATTA Fair September 2024,” to be held in Kuala Lumpur, Malaysia, from Friday, September 6, to Sunday, September 8, 2024. Staying at MIMARU means enjoying a trip to the fullest. Since the company wants Malaysian families to experience an amazing trip, the Malaysian staff at MIMARU have put together a selection of recommended Japanese food based on three themes: “Experience Japanese food,” “Masterclasses of Popular ramen,” and “Enjoy with Children.”

Staff members at MIMARU are always ready to recommend restaurants to guests that fit their interests perfectly. It only takes one bite to make them fall in love with the beauty and deliciousness of the world of Japanese food and make them curious for more. Family mealtime will be an adventurous and enjoyable occasion during the trip.

1. Experience Japanese food
The staple food in Japan is rice, and there are many rice dishes, including sushi. One of the company’s recommendations is the “donburi” (rice bowl). There are many specialty restaurants, such as oyakodon (chicken and egg bowl), gyudon (beef bowl) with sweet and spicy beef and soup, and ebi-katsudon (deep-fried shrimp cutlet bowl). Recently, “onigiri” (rice balls) have become very popular around the world. They are made by stuffing rice with various ingredients and wrapping it in seaweed. At convenience stores, they are reasonably priced at around 4-6 MYR (130-200 JPY) a piece.

Photo 1: https://cdn.kyodonewsprwire.jp/prwfile/release/
M107482/202408225251/_prw_PI1fl_z4SDgqyp.png 

2. Popular ramen masterclasses
Ramen, which has been gaining attention from around the world, is particularly attractive to foodies for its regional variety. Hokkaido is famous for its miso flavor topped with butter and corn, while Kanto is famous for its traditional soy sauce flavor. Additionally, the hardness and thickness of the noodles also differ. Recently, there has been an increase in new varieties of ramen that use secret soup recipes, homemade noodles and ingredients. One popular example of such is yuzu salt ramen. Guests can enjoy an innovative bowl of ramen that highlights the craftsmanship of Japanese people. In Japan’s major cities, ramen shops from all over the country can be found, and comparing the different varieties will become a fun part of the trip.

Photo 2: https://cdn.kyodonewsprwire.jp/prwfile/release/
M107482/202408225251/_prw_PI2fl_7u5mv5Ul.png

3. Enjoy with children
Two popular sweets that have been around in Japan for a long time are taiyaki and shaved ice. Fish-shaped taiyaki are filled with red bean paste or cream, and some traditional eateries even grill them one by one over charcoal. Shaved ice drenched in matcha is a visually stunning delicacy. If guests want to casually dine with their kids, the company recommends a conveyor belt sushi restaurant where they can choose sweets and a la carte dishes, or a more adventurous family restaurant with a wide menu and where food is delivered by a robot.

Photo 3: https://cdn.kyodonewsprwire.jp/prwfile/release/
M107482/202408225251/_prw_PI3fl_BY31A3Ab.png

The company hopes visitors to Japan enjoy staying together with their family and friends at MIMARU, an apartment hotel that offers spacious guest rooms equipped with fully furnished kitchens, located in Tokyo, Kyoto, and Osaka. About 80% of visitors to Japan are families, and approximately 400,000 international guests stay at MIMARU each year (FY2023: Results for the period April to March).

Top 7 reasons why visitors choose MIMARU
– 27 properties in the three popular cities of Tokyo, Osaka, and Kyoto
– Spacious rooms (approximately 40 m2 to 100 m2). Enough space for family and friends.
– Rooms with a kitchen and a living/dining room. Laundry facilities in the common areas are available as well.
– Friendly service by English-speaking staff, from 35 countries or regions.
– Three MIMARU properties made Trip Advisor’s “Top 20 Foreign Travelers’ Best Hotels in Japan” list two years running (*).
– One million views on MIMARU’s official Instagram content showcasing many ways to enjoy Japan.
– Convenient location. It takes about 7 hours by direct flight from Kuala Lumpur to Tokyo (Narita or Haneda) and about 6 hours to Kansai Airport. It takes about 1 hour from the airport to any MIMARU location.

(*) Three MIMARU Tokyo locations were selected in the “Voted by Travel Lovers! Foreign Travelers’ Best Hotels in Japan” list in 2019 and 2020.

Room Photos: https://cdn.kyodonewsprwire.jp/prwfile/release/
M107482/202408225251/_prw_PI4fl_5GIs9F6x.png

MIMARU Locations: https://cdn.kyodonewsprwire.jp/prwfile/release/
M107482/202408225251/_prw_PI5fl_dkaWPmzD.jpg

For each picture, please visit the link below:
https://kyodonewsprwire.jp/release/202408225251?p=images 

About Cosmos Hotel Management Co., Ltd.
– Head office: Minato Ward, Tokyo
– President: Hideki Fujioka

MIMARU Website: https://mimaruhotels.com/hotel/
Instagram: https://www.instagram.com/mimaruhotels/

Source: Cosmos Hotel Management Co., Ltd.

^{HemoHim G, produced by Kolmar BNH and distributed by Atomy is gaining a great popularity around the world (Image: Kolmar BNH)}

SEOUL, South Korea, Aug 26 (Bernama-BUSINESS WIRE) — HemoHim, a health functional food developed by Kolmar BNH (KRX: 200130), is garnering significant attention in the global market thanks to its meticulous quality control measures throughout the entire process, starting with the stringent management of raw material origins.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240823112347/en/

HemoHim is Korea’s first individually-approved health functional food designed to enhance immune function and alleviate fatigue. Developed by Kolmar BNH in 2006, it is formulated with domestic natural ingredients such as angelica gigas, cnidium officinale, and paeonia japonica. Distributed by Atomy, HemoHim is exported to about 20 countries, including the United States and China. Since its launch, it has generated over KRW 2 trillion in cumulative domestic and international sales, with exports surpassing USD 200 million.

HemoHim’s nearly 20-year consumer preference is highly attributed to the “trust earned through rigorous quality control.” Kolmar BNH, the manufacturer of HemoHim, maintains strict oversight over the cultivation of its primary raw materials—Korean angelica gigas Nakai, cnidium officinale, paeonia japonica—ensuring their safety. The company has established a dedicated food safety team to continuously share technology and provide education to raw material cultivating farms, while rigorously inspecting the safety, stability, and efficacy of these ingredients.

Furthermore, Kolmar BNH has enhanced its quality competitiveness by developing genetic testing methods to verify the country of origin, ensuring the prevention of contamination of primary raw materials with other species. In July, Kolmar BNH patented a genetic analysis method (SCAR Marker) that identifies the origin of Korean angelica gigas by recognizing specific genetic regions. Moreover, Kolmar BNH developed a genetic analysis method using PCR (polymerase chain reaction) analysis for cnidium officinalea and paeonia japonica and completed the patent registration process two years ago.

Safety was also the top priority for HemoHim G, a latest product targeting the global market. In April, Kolmar BNH published a study on HemoHim G in the SCIE-ranked journal ‘Toxicological Research,’ demonstrating its safety. Conducted according to OECD guidelines, the study holds significance not only in facilitating safety approvals in other countries but also in securing intellectual property rights with reliable results.

HemoHim G (Global) is the international version of HemoHim, Korea’s first individually-approved immune-boosting health supplement developed by Kolmar BNH over an eight-year period. The formulation has been tailored to comply with the food regulations of various countries, with adjustments made to raw materials and ingredient ratios. The product features angelica sinensis, ligusticum chuanxiong, paeonia lactiflora, all selected through rigorous provenance and quality control processes. Enhanced taste and aroma also make HemoHim G more appealing to a broader audience.

Kolmar BNH plans to continuously improve quality through ongoing research and development to support HemoHim’s growth as a globally recognized brand.

“HemoHim, now established as a leading K-health functional food brand in the global market, is manufactured through an exhaustive quality control process,” A Kolmar BNH official said. “We will continue to conduct extensive research and development to further enhance product reliability.”

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20240823112347/en/

Contact

Kolmar BNH
Jang Woo Lee
Jay.lee@kolmar.co.kr

Source : Kolmar BNH